Other reports correlate the presence of Programmed death Ligand 1 (PD-L1+) TAMs with the clinical benefit of immunotherapy, indicating that this phenotype might arise from (and likely contribute to) an IFNγ-rich anti-tumor microenvironment (reviewed in [62,69]. This evidence concerns the gene IFNG and neoplasm.